CSIMarket
 


Cue Biopharma Inc   (CUE)
Other Ticker:  
 

Cue Biopharma Inc 's Tangible Leverage Ratio

CUE's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -3.05%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.62 is above the company's typical Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 257 other companies have achieved lower Tangible Leverage Ratio than Cue Biopharma Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 685 to 1222 .

Explain Tangible Leverage Ratio?
What is CUE Market Share?
What are CUE´s Total Liabilities?


CUE Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -15.95 % -23.01 % -14.93 % 0.29 % -20.08 %
Y / Y Total Liabilities Change 3.11 % 8.67 % 2.44 % 42.95 % 66.3 %
Tangible Leverage Ratio MRQ 0.62 0.59 0.48 0.39 0.5
CUE's Total Ranking # 1222 # 685 # 1027 # 650 # 1123
Seq. Tangible Equity Change -7.26 % -16.38 % -16.24 % 29.39 % -15.05 %
Seq. Total Liabilities Change -3.05 % 1.85 % 4.16 % 0.25 % 2.17 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 258
Healthcare Sector # 492
Overall Market # 1222


Tangible Leverage Ratio Statistics
High Average Low
1.06 0.39 0.07
(Jun 30 2019)   (Mar 31 2018)




Financial Statements
Cue Biopharma Inc 's Tangible Equity $ 43 Millions Visit CUE's Balance sheet
Cue Biopharma Inc 's Total Liabilities $ 26 Millions Visit CUE's Balance sheet
Source of CUE's Sales Visit CUE's Sales by Geography


Cumulative Cue Biopharma Inc 's Tangible Leverage Ratio

CUE's Tangible Leverage Ratio for the trailling 12 Months

CUE Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -15.95 % -23.01 % -14.93 % 0.29 % -20.08 %
Y / Y Total Liabilities TTM Growth 3.11 % 8.67 % 2.44 % 42.95 % 66.3 %
Tangible Leverage Ratio TTM 0.51 0.48 0.44 0.42 0.39
Total Ranking TTM # 1143 # 4 # 975 # 450 # 5
Seq. Tangible Equity TTM Growth -7.26 % -16.38 % -16.24 % 29.39 % -15.05 %
Seq. Total Liabilities TTM Growth -3.05 % 1.85 % 4.16 % 0.25 % 2.17 %


On the trailing twelve months basis Despite of the repayements of liabilities of -3.05% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.51, above Cue Biopharma Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 252, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Cue Biopharma Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 4 to 1143.

Explain Tangible Leverage Ratio?
What is CUE Market Share?
What are CUE´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 253
Healthcare Sector # 474
Within the Market # 1143


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.67 0.37 0.14
(Sep 30 2019)   (Dec 31 2018)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
First Wave Biopharma Inc   1.66 $ 2.648  Millions$ 1.595  Millions
Promis Neurosciences inc   1.65 $ 11.121  Millions$ 6.737  Millions
Soligenix inc   1.65 $ 6.963  Millions$ 4.221  Millions
Axsome Therapeutics Inc   1.64 $ 331.349  Millions$ 202.573  Millions
Liquidia Corporation  1.57 $ 63.635  Millions$ 40.612  Millions
Maia Biotechnology Inc   1.55 $ 4.253  Millions$ 2.748  Millions
Rani Therapeutics Holdings Inc   1.52 $ 52.883  Millions$ 34.819  Millions
Avid Bioservices Inc   1.48 $ 270.967  Millions$ 183.675  Millions
Lexicon Pharmaceuticals Inc   1.44 $ 136.969  Millions$ 94.967  Millions
Vaxxinity Inc   1.42 $ 33.774  Millions$ 23.705  Millions
Sonoma Pharmaceuticals Inc   1.40 $ 7.960  Millions$ 5.675  Millions
Supernus Pharmaceuticals inc   1.37 $ 210.496  Millions$ 154.025  Millions
Pds Biotechnology Corp  1.34 $ 32.704  Millions$ 24.484  Millions
Elicio Therapeutics Inc   1.33 $ 17.701  Millions$ 13.286  Millions
Atreca inc   1.33 $ 14.302  Millions$ 10.759  Millions
Arvinas Inc   1.31 $ 601.100  Millions$ 457.200  Millions
Carisma Therapeutics Inc   1.31 $ 60.486  Millions$ 46.298  Millions
Transcode Therapeutics Inc   1.30 $ 5.788  Millions$ 4.440  Millions
Verrica Pharmaceuticals Inc   1.30 $ 54.845  Millions$ 42.303  Millions
Innoviva Inc   1.29 $ 481.901  Millions$ 372.743  Millions
Lifevantage Corp  1.29 $ 37.310  Millions$ 28.872  Millions
Eyenovia inc   1.29 $ 17.645  Millions$ 13.657  Millions
Novabay Pharmaceuticals Inc   1.29 $ 5.815  Millions$ 4.523  Millions
Equillium Inc   1.25 $ 30.191  Millions$ 24.108  Millions
Summit Therapeutics Inc   1.22 $ 119.097  Millions$ 97.565  Millions
Viracta Therapeutics Inc   1.21 $ 36.429  Millions$ 30.008  Millions
Theriva Biologics inc   1.17 $ 19.667  Millions$ 16.765  Millions
Eton Pharmaceuticals Inc   1.15 $ 14.634  Millions$ 12.682  Millions
Enanta Pharmaceuticals Inc  1.13 $ 245.540  Millions$ 216.735  Millions
Scpharmaceuticals Inc   1.13 $ 55.404  Millions$ 49.146  Millions

Date modified: 2023-11-04T19:49:25+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com